Lymphotoxin-beta receptor ligands (LTα1β2 and LIGHT) (LTβR ligands)

The Lymphotoxin-beta receptor (LTβR) ligands, primarily the lymphotoxin-alpha1-beta2 (LTα1β2) heterotrimer and LIGHT (TNFSF14), are pivotal signaling proteins within the tumor necrosis factor (TNF) superfamily (UniProt: Q06643, O43557). These ligands are expressed on the surface of activated T, B, and NK cells and are essential for the development of secondary lymphoid organs and the maintenance of immune homeostasis (PubMed: 20635363). Upon binding to the LTβR, they initiate signaling through both the classical and non-canonical NF-κB pathways, leading to the production of homeostatic chemokines such as CXCL13, CCL19, and CCL21, which coordinate lymphocyte trafficking. In chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis and Sjögren's syndrome, the over-expression of these ligands drives the formation of ectopic tertiary lymphoid structures and sustains localized inflammation (PubMed: 24106106). BG9924, also known as baminercept, is a soluble LTβR-Ig fusion protein that acts as a decoy receptor to neutralize these ligands, thereby blocking their pro-inflammatory signaling (ClinicalTrials.gov: NCT00432107). While targeting these ligands offers a specific approach to modulating lymphoid architecture, clinical trials have highlighted the need for careful patient selection and monitoring for potential immunosuppressive side effects.

Other names

LTα1β2LIGHTTNFSF14Lymphotoxin alpha1beta2CD258LT-betaLymphotoxin-beta

Decoy receptor (trap) that binds to and neutralizes the ligands LTα1β2 and LIGHT, preventing their interaction with the cell-surface lymphotoxin-beta receptor (LTβR).